The global continuous glucose monitorin(CGM) market was valued at USD 0.37 billion in 2012 and is expected to grow at a CAGR of 13.6% from 2013 to 2019, to reach an estimated value of USD 0.91 billion in 2019.
Browse Global Sterilization Equipment and Disinfectants Market Report with Full TOC athttp://www.transparencymarketresearch.com/continuous-glucose-monitoring.html
Continuous glucose monitoring systems (CGMS) are real time glucose monitoring devices that measure and display the glucose level of the interstitial fluid in the skin cells of the patient. These devices help patients manage diabetes (Type 1 and Type 2) in a more efficient manner. CGM devices typically comprise a sensor, transmitter and a receiver. The sensor is placed underneath the skin for monitoring glucose levels and is attached to the transmitter that relays the information to the monitor. Until recently, management of diabetes involved the use of conventional blood glucose meters that provided a single time snapshot of the patient's blood glucose level. However, demand for real time monitoring, minimally invasive and effective diabetes management solutions led to the advent of CGM devices. Rise in the incidence of diabetes globally coupled with increasing awareness of such devices that possess the ability to detect hyper and hypoglycemic events in real time will fuel the growth of this market during the forecast period.
CGM is a rapidly evolving market supported by increasing adoption of these systems by hospitals and individual practitioners who further encourage their patients to use these devices. However, CGM systems are not meant to be replaced by the traditional diabetes management devices. Hence, the technology still requires innovation in terms of accuracy and precision. Reimbursement issues, high cost of devices and low market penetration rates are some of the factors that are expected to hinder market growth in the near future. Medtronic's Guardian Real Time CGM System accounted for the largest share of the global marketin 2012, accounting for a share of over 40%. The product's first mover advantage in the market, proper positioning and marketing of the product, and ease of convenience and usability helped it achieve this leadership position. Dexcom's fourth generation product, namely, Dexcom G4 Platinum is anticipated to witness the highest market growth at a CAGR of 22.6% during the forecast period. G4 Platinum is the most recently launched device (2012) and is the most technologically advanced, offering more accuracy and reliability as compared to other commercially available devices. In addition, integration of this device with insulin pumps from various other manufacturers like Johnson & Johnson and Tandem Diabetes Care would also drive the growth of this market segment.
Geographically, North America captured majority share of the global continuous glucose monitoring market in 2012. Increase in type I diabetic population along with rise in geriatric population which will in turn spur the demand for regular monitoring of glucose levels will fuel the growth of this market. Major players of this market are domiciled in this region, which allows easy market penetration and will also contribute towards market growth. The European CGM market is in a rapidly evolving state and contributed the largest share of the total CGM market revenue in 2012. Asia-Pacific is expected to witness tremendous increase its market share and emerge as the fastest growing region, reporting a CAGR of 16.9% during the forecast period. Economic developments, presence of a large patient pool, rising patient awareness, increasing disposable income and changing lifestyle are some of the significant factors that are poised to increase the demand for CGM systems in this region.
Key players in this market include Medtronic, Inc., Dexcom, Inc. and Abbott Diabetes Care. Medtronic was the leading player of this market in 2012, accounting for a share of over 50%. Abbott saw a decline in its market share due to withdrawal of Free Style Navigator from the U.S. market in the fourth quarter of 2011. However, the expected launch of Free Style Navigator ll in 2014 in the U.S. market would help the company restore its market position. Other companies such as Johnson & Johnson, Bayer Healthcare and Tandem Diabetes Care are adopting the strategy of partnerships and collaboration to enter this dynamic market.
The global continuous glucose monitoring market is segmented as follows:
Continuous Glucose Monitoring Market, by Device/Brand
- Guardian Real Time CGM System
- Dexcom Seven Plus
- Dexcom G4 Platinum
- FreeStyle Navigator
- MiniMed Paradigm Revel/Veo System
BrowseSterilizationEquipmentandDisinfectants Market athttp://www.transparencymarketresearch.com/continuous-glucose-monitoring.html
Continuous Glucose Monitoring Market, by Geography
- North America
- Rest of the World (RoW)
Browse all Medical Devices Market Research Reports @http://www.transparencymarketresearch.com/medical-devices-market-reports-6.html